A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 13 Mar 2024 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.
- 13 Mar 2024 Planned primary completion date changed from 1 Dec 2024 to 11 Mar 2024.
- 19 Sep 2022 Planned End Date changed from 1 Dec 2026 to 1 Dec 2024.